Claro Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 13 Year, 10 Months
- Last Filing with ROC 31 Mar 2020
- Revenue Growth 4.54%
- Profit Growth -118.96%
- Ebitda -67.57%
- Net Worth -0.62%
- Total Assets -3.94%
About Claro Pharmaceuticals
Claro Pharmaceuticals Private Limited (CPPL) is a Private Limited Indian Non-Government Company incorporated in India on 28 March 2011 and has a history of 13 years and ten months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2020. It's a company limited by shares with an authorized capital of Rs 2.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Chevuru Hariprasad, Chevuru Komaleswari, and Arun Singh serve as directors at the Company.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24232TG2011PTC073540
-
Company No.
073540
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
28 Mar 2011
-
Date of AGM
31 Dec 2020
-
Date of Balance Sheet
31 Mar 2020
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Claro Pharmaceuticals?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arun Singh
|
Additional Director | 21-Mar-2022 | Current |
|
Chevuru Hariprasad
|
Director | 16-Jul-2014 | Current |
|
Chevuru Komaleswari
|
Additional Director | 09-Jan-2014 | Current |
Financial Performance of Claro Pharmaceuticals.
Claro Pharmaceuticals Private Limited, for the financial year ended 2020, experienced modest growth in revenue, with a 4.54% increase. The company also saw a substantial fall in profitability, with a 118.96% decrease in profit. The company's net worth dipped by a decrease of 0.62%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Claro Pharmaceuticals?
In 2019, Claro Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Arsa Life Care Private LimitedArun Singh is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Claro Pharmaceuticals?
Unlock and access historical data on people associated with Claro Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Claro Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Claro Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
